IL158204A - Vaccine composition for inducing a protective immune response against the west nile virus - Google Patents
Vaccine composition for inducing a protective immune response against the west nile virusInfo
- Publication number
- IL158204A IL158204A IL158204A IL15820403A IL158204A IL 158204 A IL158204 A IL 158204A IL 158204 A IL158204 A IL 158204A IL 15820403 A IL15820403 A IL 15820403A IL 158204 A IL158204 A IL 158204A
- Authority
- IL
- Israel
- Prior art keywords
- dna
- oligonucleotide
- artificial
- virus
- wnv
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 82
- 229960005486 vaccine Drugs 0.000 title claims description 78
- 241000710886 West Nile virus Species 0.000 title claims description 48
- 230000028993 immune response Effects 0.000 title claims description 14
- 230000001681 protective effect Effects 0.000 title claims description 14
- 230000001939 inductive effect Effects 0.000 title claims description 11
- 239000013612 plasmid Substances 0.000 claims description 111
- 241000700605 Viruses Species 0.000 claims description 105
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 108091034117 Oligonucleotide Proteins 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 52
- 230000002163 immunogen Effects 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 42
- 241001465754 Metazoa Species 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 241000178270 Canarypox virus Species 0.000 claims description 29
- 241000283073 Equus caballus Species 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 23
- 238000001727 in vivo Methods 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 230000001717 pathogenic effect Effects 0.000 claims description 19
- 108010076039 Polyproteins Proteins 0.000 claims description 18
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 15
- 244000052769 pathogen Species 0.000 claims description 11
- 241001529453 unidentified herpesvirus Species 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000002238 attenuated effect Effects 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 241000700663 Avipoxvirus Species 0.000 claims description 5
- 241000700662 Fowlpox virus Species 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 103
- 108091033319 polynucleotide Proteins 0.000 description 49
- 102000040430 polynucleotide Human genes 0.000 description 49
- 239000002157 polynucleotide Substances 0.000 description 49
- 239000013604 expression vector Substances 0.000 description 37
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 201000006449 West Nile encephalitis Diseases 0.000 description 29
- 206010057293 West Nile viral infection Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000010276 construction Methods 0.000 description 22
- 241000271566 Aves Species 0.000 description 21
- 108091008146 restriction endonucleases Proteins 0.000 description 21
- 238000000246 agarose gel electrophoresis Methods 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 19
- 108700026244 Open Reading Frames Proteins 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 18
- 241000287828 Gallus gallus Species 0.000 description 17
- 235000013330 chicken meat Nutrition 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 101100060007 Caenorhabditis elegans mig-22 gene Proteins 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 101710172711 Structural protein Proteins 0.000 description 10
- 108020000999 Viral RNA Proteins 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000009004 PCR Kit Methods 0.000 description 7
- 238000010240 RT-PCR analysis Methods 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 7
- 206010014599 encephalitis Diseases 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 229940031348 multivalent vaccine Drugs 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 241000283086 Equidae Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- -1 NS2B Proteins 0.000 description 6
- 101710144111 Non-structural protein 3 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108010008038 Synthetic Vaccines Proteins 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 229940124551 recombinant vaccine Drugs 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 101710126499 Envelope glycoprotein E Proteins 0.000 description 5
- 208000000666 Fowlpox Diseases 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 101800001030 Non-structural protein 2A Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 101710204837 Envelope small membrane protein Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 4
- 101710088839 Replication initiation protein Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 3
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 2
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 241000702626 Infectious bursal disease virus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 241000710912 Kunjin virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101800001020 Non-structural protein 4A Proteins 0.000 description 2
- 101800001019 Non-structural protein 4B Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700638 Raccoonpox virus Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 101150050057 UL43 gene Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(z)-octadec-9-enoyl]oxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 241001516406 Avian orthoreovirus Species 0.000 description 1
- 241000606560 Avibacterium avium Species 0.000 description 1
- 241000606591 Avibacterium gallinarum Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101800001632 Envelope protein E Proteins 0.000 description 1
- 241000230501 Equine herpesvirus sp. Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001148547 Mycoplasma gallinarum Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241000543245 Pasteurella multocida subsp. gallicida Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101800001127 Protein prM Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 101150093191 RIR1 gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101150048066 UL45 gene Proteins 0.000 description 1
- 101150081415 UL55 gene Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 101150029683 gB gene Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940010310 propylene glycol dioleate Drugs 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
158204/2 A vaccine composition to induce a protective immune response against the West Nile Virus Merial C. 148491 RECOMBINANT VACCINE AGAINST WEST NILE VIRUS The present invention relates to in vivo and in vitro expression vectors comprising and expressing at least one polynucleotide of the West Nile fever virus, as well as immunogenic compositions and vaccines against West Nile fever. It also relates to methods for immunizing and vaccinating against this virus.
The West Nile fever virus (WNV) was first identified in man in 1937 in Ouganda in the West Nile Province (Zeller H. G., Med. Trop., 1999, 59, 490-494).
Widespread in Africa, it is also encountered in India, Pakistan and the Mediterranean basin and was identified for the first time in the USA in 1999 in New York City (Anderson J. F. et al., Science, 1999, 286, 2331-2333).
The West Nile fever virus affects birds as well as mammals, together with man.
The fever is characterized in birds by an attack of the central nervous system and death. The lesions include encephalitis, hemorrhages in the myocardium and hemorrhages and necroses in the intestinal tract.
In chickens/ experimental infections by subcutaneous inoculations of the West Nile fever virus isolated on crows led to necroses of the myocardium, nephrites and pneumonia 5 to 10 days after inoculation and moderate to severe encephalitis 21 days after inoculation (Senne D. A. et al., Avian Disease, 2000, 44, 642-649).
The West Nile fever virus also affects horses, particularly in North Africa and Europe (Cantile C. et al., Equine Vet. J., 2000, 32 (1 ), 31 -35). These horses reveal signs of ataxia, weakness of the rear limbs, paresis evolving towards tetraplegia and death. Horses and camels are the main animals manifesting clinical signs in the form of encephalitis.
Anti-WNV antibodies were detected in certain rodents, in livestock, particularly bovines and ovines, as well as in domestic animals, particularly in the dog (Zeller H. G., Med. Trop., 1999, 59, 490-494; Lundstrom J. O., Journal of Vector Ecology, 1999, 24 (1 ), 1 -39).
The West Nile fever virus also affects with a number of symptoms the human species (Sampson B. A., Human Pathology, 2000, 31 (5), 527-531 ; Marra C. M., Seminars in Neurology, 2000, 20 (3), 323-327).
The West Nile fever virus is transmitted to birds and mammals by the bites of certain mosquitoes (e.g.
Culex, Aedes, Anopheles) and ticks.
Wild and domestic birds are a reservoir for the West Nile virus and a propagation vector as a result of their migrations. - 2 - 158204/2 The virions of the West Nile fever virus are spherical particles with a diameter of 50 nm constituted by a lipoproteic envelope surrounding an icosahedric nucleocapsid containing a positive polarity, single-strand RNA.
A single open reading frame (ORF) encodes all the viral proteins in the form of a polyprotein. The cleaving and maturation of this polyprotein leads to the production of about ten different viral proteins. The structural proteins are encoded by the 5' part of the genome and correspond to the nucleocapsid designated C (14 kDa), the envelope glycoprotein designated E (50 kDa), the pre-membrane protein designated prM (23 kDa), the membrane protein designated M (7 kDa). The non-structural proteins are encoded by the 3' part of the genome and correspond to the proteins NS1 (40 kDa), NS2A (19 kDa), NS2B (14 kDa), NS3 (74 kDa), NS4A (15 kDa), NS4B (29 kDa), NS5 (97 kDa).
Parrish C. R. et al. (J. Gen. Virol., 1991 , 72, 1645-1653), Kulkami A. B. et al. (J. Virol., 1992, 66 (6), 3583-3592) and Hill A. B. et al. (J. Gen. Virol., 1992, 73, 1115-1123), on the basis of the vaccinia virus, constructed in vivo expression vectors containing various inserts corresponding to nucleotide sequences coding for non-structural proteins of the Kunjin virus, optionally associated with structural proteins. These vectors were administered to the mouse to evaluate the immune cell response. The authors stress the importance of the cell response, which is essentially stimulated by non-structural proteins and especially NS3, NS4A and NS4B. These articles reveal the difficulty in providing a good vaccination strategy against West Nile fever.
Schultz et al. provides an update on different aspects of antiviral DNA vaccine research done between 1998 and 2000 (Intervirology, 2000; 43:197-217).
David et al., reported that west nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be, used in enzyme-linked immunosorbent assays (Journal of Virology, 2001 , vol 75(9): 4040-4047).
Chang et al., reported on a single intramuscular injection of recombinant plasmid DNA that induces protective immunity and prevents Japanese encephalitis in mice (Journal of Virology, 2000, vol 74(9):4244- 4252).
WO 00/12128 discloses that compositions of truncated flaviral envelope protein and flaviral nonstructural protein induce high titer virus neutralizing antibodies.
US 2003/0022849 discloses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus virus and an immunogenic flavivirus antigen of a second flavivirus.
US 5505941 discloses a method for inducing an immunological response in a mammal or avian host to a pathogen by inoculating the mammal or avian host with a synthetic recombinant avipox virus modified by the presence, in a non-essential region of the avipox genome, of DNA from any source which codes for and expresses an antigen of the pathogen. - 2a - 158204/1 Hitherto there is no vaccine preventing infection by the WN virus.
Summary of the Invention In one of its aspects the present invention provides a vaccine composition to induce a protective immune response against West Nile virus (WNV) in an animal susceptible to WNV, said composition comprising a vector comprising a recombinant virus or DNA plasmid that encodes and expresses in vivo in the animal WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E, provided that when said virus is avipox virus, said expressed protein is different from WNV polyprotein prM-M-E.
In another one of its aspects the present invention provides a method for inducing a protective immune response against WNV in an animal comprising administering to the animal the vaccine composition of the invention.
In still another one of its aspects the present invention provides a method for inducing a protective response against WNV in an animal comprising administering to the animal the composition of the invention, wherein the composition additionally comprises an adjuvant.
In still yet another one of its aspects the present invention provides a method for inducing a protective immune response against WNV and a second pathogen in an animal comprising administering to the animal the vaccine composition of the invention.
In an additional aspect the present invention provides a method for inducing a protective immune response against WNV in an animal comprising administering to the animal (a) the vaccine composition of the invention, and (b) a WNV isolated antigen, immunogen or epitope thereof, wherein (a) is administered prior to (b) in a prime-boost regimen, or (b) is administered prior to (a) in a prime-boost regimen, or (a) and (b) are administered together, either sequentially or in admixture.
The present invention relates to a means for preventing and/or combating diseases caused by the WN virus.
Another objective of the invention is to propose such a means usable in different animal species sensitive to the disease caused by said virus and in particular equine and avian species.
Another objective of the invention is to propose immunization and vaccination methods for the target species.
Yet another objective of the invention is to propose means and methods making it possible to ensure a differential diagnosis.
Thus, the first object of the invention is in vitro and/or in vivo expression vectors comprising a polynucleotide encoding the envelope protein E of the WN virus. These vectors also comprise the elements necessary for the expression of the polynucleotide in the host cell. 3 In addition to the polynucleotide encoding E, the expression vectors according to the invention can comprise one or more other polynucleotides encoding other proteins of the WN virus, preferably structural proteins of the WN virus and said sequences are preferably chosen from among those encoding the pre-membrane protein prM and the membrane protein M.
The vector preferably comprises a polynucleotide forming a single encoding frame corresponding e.g. to prM-E, M-E and more particularly prM-M-E. A vector comprising several separate polynucleotides encoding the different proteins (e.g. prM and/or and E) also falls within the scope of the present invention. The vector, more particularly in vivo, can also comprise polynucleotides corresponding to more than one WN virus strain, particularly two or more polynucleotides encoding E or prM-M-E of different strains. As will be shown hereinafter, the vector, particularly in vivo, can comprise one or more nucleotide sequences encoding immunogens of other pathogenic agents and/or cytokins.
According to a preferred embodiment of the invention, the expression vector comprises a polynucleotide encoding prlvUM-E and preferably in a single reading frame.
The term polynucleotide encoding a protein of the WN virus mainly means a DNA fragment encoding said protein, or the complementary strand of said DNA fragment. An RNA is not excluded.
In the sense of the invention, the term protein covers fragments, including peptides and polypeptides. By definition, the protein fragment is immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein.
Preferably the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the invention comprises at least one epitope or antigenic determinant. The term epitope relates to a protein site able to induce an immune reaction of the humoral type (B cells) and/or cellular type (T cells).
Thus, the minimum structure of the polynucleotide is that encoding an epitope or antigenic determinant of the protein in question. A polynucleotide encoding a fragment of the total protein more particularly comprises a minimum of 21 nucleotides, particularly at least 42 nucleotides and preferably at least 57, 87 or 150 consecutive nucleotides of the sequence in question. Epitope determination procedures are well known to the one skilled in the art and it is more particularly possible to use overlapping peptide libraries (Hemmer B. et al., Immunology Today, 1998, 19 (4), 163-168), Pepscan (Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1984, 81 (13), 3998-4002; Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1985, 82 (1 ), 178-182; Van der Zee R. et al., Eur. J. Immunol., 1989, 19 (1 ), 43-47; Geysen H. M., Southeast Asian J. Trop. Med. Public Health, 1990, 21 (4), 523-533; Multipin® Peptide Synthesis Kits de Chiron) and algorithms (De Groot A. et al., Nature Biotechnology, 1999, 17, 533-561 ).
In particular the polynucleotides according to the invention comprise the nucleotide sequence encoding one or two transmembrane domains and preferably two of them, located in the terminal part C of the protein E. 4 For the WNV NY99 strain, these domains correspond to amino acid sequences 742 to 766 and 770 to 791 of GenBank AF196835.
Elements necessary for the expression of the polynucleotide or polynucleotides are present. In minimum manner, this consists of an initiation codon (ATG), a stop codon and a promoter, as well as a polyadenylation sequence for the plasmids and viral vectors other than poxviruses. When the polynucleotide encodes a polyprotein fragment, e.g. prM-E, M-E, prM-M-E, an ATG is placed at 5' of the reading frame and a stop codon is placed at 3'. As will be explained hereinafter, other elements making it possible to control the expression could be present, such as enhancer sequences, stabilizing sequences and signal sequences permitting the secretion of the protein.
The present invention also relates to preparations comprising such expression vectors. It more particularly relates to preparations comprising one or more in vivo expression vectors, comprising and expressing one or more of the above polynucleotides, including that encoding E, in a pharmaceutically acceptable excipient or vehicle.
According to a first embodiment of the invention, the other vector or vectors in the preparation comprise and express one or more other proteins of the WN virus, e.g. prM, M, prM-M.
According to another embodiment, the other vector or vectors in the preparation comprise and express one or more proteins of one or more other WN vims strains. In particular, the preparation comprises at least two vectors expressing, particularly in vivo, polynucleotides of different WN strains encoding the same proteins and/or for different proteins, preferably for the same proteins. This is more particularly a matter of vectors expressing in vivo E or prM-M-E of two, three or more different WN- strains. The invention is also directed at mixtures of vectors expressing prM, M, E, prM-M, prM-E or M-E of different strains.
According to yet another embodiment and as will be shown in greater detail hereinafter, the other vector or vectors in the preparation comprise and express one or more cytokins and/or one or more immunogens of one or more other pathogenic agents.
The invention also relates to various combinations of these different embodiments.
The preparations comprising an in vitro or in vivo expression vector comprising and expressing a polynucleotide encoding prM-M-E constitute a preferred embodiment of the invention.
According to a special embodiment of the invention, the in vivo or In vitro expression vectors comprise as the sole polynucleotide or polynucleotides of the WN virus, a polynucleotide encoding the protein E, optionally associated with prM and/or M, preferably encoding prM-M-E and optionally a signal sequence of the WN virus. 5 According to a special embodiment, one or more of the non-structural proteins NS2A, NS2B and NS3 are expressed jointly with the structural proteins according to the invention, either via the same expression vector, or via their own expression vector. They are preferably expressed together on the basis of a single polynucleotide.
Thus, the invention also relates to an in vivo or in vitro expression vector comprising the polynucleotide encoding NS2A, NS2B, NS3, their combinations and preferably for NS2A-NS2B-NS3. Basically said vector can be one of the above-described vectors comprising a polynucleotide encoding one or more structural proteins, particularly E or prM-M-E. As an alternative, the invention relates to a preparation as described hereinbefore, also incorporating at least one of these vectors expressing a non-structural protein and optionally a pharmaceutically acceptable vehicle or excipient.
In order to implement the expression vectors according to the invention, the one skilled in the art has various strains of the WN virus and the description of the nucleotide sequence of their genome, cf. particularly Savage H. M. et al. (Am. J. Trop.' Med. Hyg. 1999, 61 (4), 600-611 ), table 2, which refers to 24 WN virus strains and gives access references to polynucleotide sequences in GenBank.
Reference can e.g. be made to strain NY99 (GenBank AF196835). In GenBank, for each protein the corresponding DNA sequence is given (nucleotides 466-741 for prM, 742-966 for M, 967-2469 for E, or 466-2469 for prM-M-E, 3526-4218 for NS2A, 4219-4611 for NS2B and 4612-6468 for NS3, or 3526-6468 for NS2A-NS2B-NS3). By comparison and alignment of the sequences, the determination of a polynucleotide encoding such a protein in another WNV strain is immediate.
It was indicated hereinbefore that polynucleotide was understood to mean the sequence encoding the protein or a fragment or an epitope specific to the WN virus.. Moreover, by equivalence, the term polynucleotide also covers the corresponding nucleotide sequences of the different WN virus strains and nucleotide sequences differing by the degeneracy of the code.
Within the family of WN viruses, identity between amino acid sequences prM-M÷E relative to that of NY99 is equal to or greater than 90%. Thus, the invention covers polynucleotides encoding an amino acid sequence, whose identity with the native amino acid sequence is equal to or greater than 90%, particularly 92%, preferably 95% and more specifically 98%. Fragments of these homologous polynucleotides specific with respect to WN viruses, are also considered equivalents.
Thus, on referring to a polynucleotide of the WN virus, this term covers equivalent sequences within the sense of the invention.
It has also been seen that the term protein covers immunologically active peptides and polypeptides. For the requirements of the invention, it covers: a) corresponding proteins of the different WN virus strains, b) proteins differing therefrom, but maintaining with a native WN protein an identity equal to or greater than 90%, particularly 92%, preferably 95% and more specifically 98%.
Thus, on referring to a protein of the WN virus, this term covers equivalent proteins within the sense of the invention.
Different WN virus strains are accessible in collections, particularly in the American Type Culture Collection (ATCC), e.g. under access numbers VR-82 or VR-1267. The Kunjin virus is in fact considered to be a WN virus.
According to the invention, preferably the polynucleotide also comprises a nucleotide sequence encoding a signal peptide, located upstream of the expressed protein in order to ensure the secretion thereof. It can consequently be an endogenic sequence, i.e. the natural signal sequence when it exists (coming from the same WN virus or another strain). For example, for the NY99 WN virus, the endogenic signal sequence of E corresponds to nucleotides 922 to 966 of the GenBank sequence and for prM it is a matter of nucleotides 421 to 465. It can also be a nucleotide sequence encoding a heterologous signal peptide, particularly that encoding the signal peptide of the human tissue plasminogen activator (tPA) (Hartikka J. et al., Human Gene Therapy, 1996, 7, 1205-1217). The nucleotide sequence encoding the signal peptide is inserted in frame and upstream of the sequence encoding E or its combinations, e.g. prM-M-E.
According to a first embodiment of the invention, the' in vivo expression vectors are viral vectors.
These expression vectors are advantageously poxviruses, e.g. the vaccinia virus or attenuated mutants of the vaccinia virus, e.g. MVA (Ankara strain) (Stickl H. and Hochstein-Mintzel V., Munch. Med. Wschr., 1971 , 1 13, 1 149-1 153; Sutter G. et al., Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 10847-10851 ; commercial strain ATCC VR: 508; MVA being obtained after more than 570 passages of the Ankara vaccine strain on chicken embryo fibroblasts) or NYVAC (its construction being described in US-A-5 494 807, particularly in examples 1 to 6, said patent also describing the insertion of heterologous genes in sites of this recombinant and the use of matched promoters - reference also to be made to WO-A-96/40241 ), avipox (in particular canarypox, fowlpox, pigeonpox, quailpox), swinepox, raccoonpox and camelpox, adenoviruses, such as avian, canine, porcine, bovine, human adenoviruses and herpes viruses, such as equine herpes virus (EHV serotypes 1 and 4), canine herpes virus (CHV), feline herpes virus (FHV), bovine herpes viruses (BHV serotypes 1 and 4), porcine herpes virus (PRV), Marek's disease virus (MDV serotypes 1 and 2), turkey herpes virus (HVT or MDV serotype 3), and duck herpes virus. When a herpes virus is used, the vector HVT is preferred for the vaccination of the avian species and the vector EHV for the vaccination of horses.
According to one of the preferred embodiments of the invention, the poxvirus expression vector is a canarypox or a fowlpox, whereby such poxviruses can possibly be attenuated. Reference can be made to the canarypox commercially available from ATCC under access number VR-1 1 . Attenuated canarypox viruses were- described in US-A-5,756,103 and WO-A-01/05934. Numerous fowlpox virus vaccination strains are available, e.g. the DIFTOSEC CT© strain marketed by MERIAL and the NOBILIS© VARIOLE vaccine marketed by Intervet.
For poxviruses, the one skilled in the art can refer to WO-A-90/12882 and more particularly for the vaccinia virus to US-A-4,769,330; US-A-4,722,848; US-A-4,603,112; US-A-5, 110,587; US-A-5,494,807; US-A-5,762,938; for fowlpox to US-A-5, 174,993; US-A-5,505,941 ; US-5,766,599; for canarypox to US-A-5,756,103; for swinepox to US-A-5,382,425 and for raccoonpox to WO-A-00/03030.
When the expression vector is a vaccinia virus, the insertion sites for the polynucleotide or polynucleotides to be expressed are in particular the gene of thymidine kinase (TK), the gene of hemagglutinin (HA), the region of the inclusion body of the A type (ATI). In the case of canarypox, the insertion sites are more particularly located in or are constituted by ORFs, C3, C5 and C6. In the case of fowlpox, the insertion sites are more particularly located in or constituted by the ORFs F7 and F8.
The insertion of genes in the MVA virus has been described in various publications, including Carroll M. W. et al., Vaccine, 1997, 15 (4), 387-394; Stittelaar K. J. et al., J. Virol., 2000, 74 (9), 4236-4243; Sutter G. et al., 1994, Vaccine, 12 (11 ), 1032-1040, to which the one skilled in the art can refer. The complete MVA genome is described in Antoine G., Virology, 1998, 244, 365-396, which enables the one skilled in the art to use other insertion sites or other promoters.
Preferably, when the expression vector is a poxvirus, the polynucleotide to be expressed is inserted under the control of a specific poxvirus promoter, particularly the vaccine promoter 7.5 kDa (Cochran et al., J. Virology, 1985, 54, 30-35), the vaccine promoter I3L (Riviere et al„ J. Virology, 1992, 66, 3424-3434), the vaccine promoter HA (Shida, Virology, 1986, 150, 451-457), the cowpox promoter ATI (Funahashi et al., J. Gen. Virol., 1988, 69, 35-47), or the vaccine promoter H6 (Taylor J. et al., Vaccine, 1988, 6, 504-508; Guo P. et al. J. Virol., 1989, 63, 4189-4198; Perkus M. et al., J. Virol., 1989, 63, 3829-3836).
Preferably, for the vaccination of mammals the expression vector is a canarypox. Preferably, for the vaccination of avians, particularly chickens, ducks, turkeys and geese, the expression vector is a canarypox or a fowlpox.
When the expression vector is a herpes virus HVT, appropriate insertion sites are more particularly located in the BamHI I fragment or in the BamHI M fragment of HVT. The HVT BamHI I restriction fragment comprises several open reading frames (ORFs) and three intergene regions and comprises several preferred insertion zones, namely the three intergene regions 1 , 2 and 3, which constitute preferred regions, and ORF UL55 (FR-A-2 728 795, US-A-5 980 906). The HVT BamHI M restriction fragment comprises ORF UL43, which is also a preferred insertion site (FR-A-2 728 794, US-A-5 733 554).
When the expression vector is an EHV-1 or EHV-4 herpes virus, appropriate insertion sites are in particular TK, UL43 and UL45 (EP-A-668355).
Preferably, when the expression vector is a herpes virus, the polynucleotide to be expressed is inserted under the control of a strong eukaryote promoter, preferably the CMV-IE promoter. These strong promoters are described hereinafter in the part of the description relating to plasmids.
According to a second embodiment of the invention, the in vivo expression vectors are plasmidic vectors known as plasmids.
The term plasmid covers any DNA transcription unit in the form of a polynucleotide sequence comprising a polynucleotide according to the invention and the elements necessary for its in vivo expression. Preferably there is a supercoiled or non-supercoiled, circular plasmid. The linear form also falls Within the scope of the invention.
Each plasmid comprises a promoter able to ensure, in the host cells, the expression of the polynucleotide inserted under its dependency. In general, it is a strong eukaryote promoter. The preferred strong eukaryote promoter is the early cytomegalovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin such as the rat or guinea pig. The CMV-IE promoter can comprise the actual promoter part, which may or may not be associated with the enhancer part. Reference can be made to EP-A-260 148, EP-A-323 597, US-A-5 168 062, US-A-5 385 839, US-A-4 968 615, WO-A-87/03905. Preference is given to human CMV-IE (Boshart M. et al., Cell., 1985, 41 , 521-530) or murine CMV-IE.
In more general terms, the promoter has either a viral or a cellular origin. A strong viral promoter other than CMV-IE is the early/late promoter of the SV40 virus or the LTR promoter of the Rous sarcoma virus. A strong cellular promoter is the promoter of a gene of the cytoskeleton, such as e.g. the desmin promoter (Kwissa M. et al., Vaccine, 2000, 18 (22), 2337-2344), or the actin promoter (Miyazaki J. et al., Gene, 1989, 79 (2), 269-277).
By equivalence, the sub-fragments of these promoters, maintaining an adequate promoting activity are included within the present invention, e.g. truncated CMV-IE promoters according to WO-A-98/00166. The notion of the promoter according to the invention consequently includes derivatives and sub-fragments maintaining an adequate promoting activity, preferably substantially similar to that of the actual promoter from which they are derived. For CMV-IE, this notion comprises the actual promoter part and/or the enhancer part, as well as derivatives and sub-fragments.
Preferably, the plasmids comprise other expression control elements. It is in particular advantageous to incorporate stabilizing sequences of the intron type, preferably intron II of the rabbit β-globin gene (van Ooyen et al., Science, 979, 206: 337-344).
As the polyadenylation signal (polyA) for the plasmids and viral vectors other than poxviruses, use can more particularly be made of the one of the bovine growth hormone (bGH) gene (US-A-5 122 458), the one of the rabbit β-globin gene or the one of the SV40 virus.
The other expression control elements usable in plasmids can also be used in herpes virus expression vectors.
According to another embodiment of the invention, the expression vectors are expression vectors used for the in vitro expression of proteins in an appropriate cell system. The proteins can be harvested in the culture supernatant after or not after secretion (if there is no secretion a cell lysis is done), optionally concentrated by conventional concentration methods, particularly by ultrafiltration and/or purified by conventional purification means, particularly affinity, ion exchange or gel filtration-type chromatography methods.
Production takes place by the transfection of mammal cells by plasmids, by replication of viral vectors on mammal cells or avian cells, or by Baculovirus replication (US-A-4 745 051 ; Vialard J. et al., J. Virol., 1990 64 (1 ), 37-50; Verne A., Virology, 1988, 167, 56-71 ), e.g. Autographa californica Nuclear Polyhedrosis Virus AcNPV, on insect cells (e.g. Sf9 Spodoptera frugiperda cells, ATCC CRL 171 1 ). Mammal cells which can be used are in particular hamster cells (e.g. CHO or BHK-21 ) or monkey cells (e.g. COS or VERO). Thus, the invention also covers expression vectors incorporating a polynucleotide according to the invention, the thus produced WN proteins or fragments and the preparations containing the same.
Thus, the present invention also relates to WN protein-concentrated and/or purified preparations. When the polynucleotide encodes several proteins, they are cleaved, and the aforementioned preparations then contain cleaved proteins.
The present invention also relates to immunogenic compositions and vaccines against the WN virus comprising at least one in vivo expression vector according to the invention and a pharmaceutically acceptable excipient or vehicle and optionally an . adjuvant.
The immunogenic composition notion covers any composition which, once administered to the target species, induces an. immune response directed against the WN virus. The term vaccine is understood to mean a composition able to induce an effective protection. The target species are equines, canines, felines, bovines, porcines, birds, preferably the horse, dog, cat, pig and in the case of birds geese, turkeys, chickens and ducks and which by definition covers reproducing animals, egg-layers and meat animals.
The pharmaceutically acceptable vehicles or excipients are well known to the one skilled in the art. For example, it can be a 0.9% NaCI saline solution or a phosphate buffer. The pharmaceutically acceptable vehicles or excipients also cover any compound or combination of compounds facilitating the administration of the vector, particularly the transfection, and/or improving preservation.
The doses and dose volumes are defined hereinafter in the general description of immunization' and vaccination methods.
The immunogenic compositions and vaccines according to the invention preferably comprise one or more adjuvants, particularly chosen from among conventional adjuvants. Particularly suitable within the scope of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), particularly oligodeoxyribonucleotide sequences having one ore more non-methylated CpG units (Klinman D. M. et al., Proc. Natl. Acad. Sci., USA, 1996, 93, 2879-2883; WO-A1-98/16247), (3) an oil in water emulsion, particularly the SPT emulsion described on p 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M. Newman, Plenum Press 1995, and the emulsion MF59 described on p 183 of the same work, (4) cation lipids containing a quaternary ammonium salt, (5) cytokins or (6) their combinations or mixtures.
The oil in water emulsion (3), which is particularly appropriate for viral vectors, can in particular be based on: - light liquid paraffin oil (European pharmacopoeia type), - isoprenoid oil such as squalane, squalene, - oil resulting from the oligomerization of alkenes, particularly isobutene or decene, - esters of acids or alcohols having a straight-chain alkyl group, more particularly vegetable oils, ethyl oleate, propylene glycol, di(caprylate/caprate), glycerol tri(caprylate/caprate) and propylene glycol dioleate, - esters of branched, fatty alcohols or acids, particularly isostearic acid esters.
The oil is used in combination with emulsifiers to form the emulsion. The emulsifiers are preferably nonionic surfactants, particularly: - esters of on the one hand sorbitan, mannide (e.g. anhydromannitol oleate), glycerol, polyglycerol or propylene glycol and on the other hand oleic, isostearic, ricinoleic or hydroxystearic acids, said esters being optionally ethoxylated, - polyoxypropylene-polyoxyethylene copolymer blocks, particularly Pluronic©, especially L121.
Among the type (1 ) adjuvant polymers, preference is given to polymers of crosslinked acrylic or methacrylic acid, particularly crosslinked by pplyalkenyl ethers of sugars or polyalcohols. These compounds are known under the name carbomer (Pharmeuropa, vol. 8, no. 2, June 1996). The one skilled in the art can also refer to US-A-2 909 462, which describes such acrylic polymers crosslinked by a polyhydroxyl compound having at least three hydroxyl groups, preferably no more than eight such groups, the hydrogen atoms of at least three hydroxyl groups being replaced by unsaturated, aliphatic radicals having at least two carbon atoms. The preferred radicals are those containing 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals can also contain other substituents, such as methyl.
Products sold under the name Carbopol© (BF Goodrich, Ohio, USA) are particularly suitable. They are in particular crosslinked by allyl saccharose or by allyl pentaerythritol. Among them particular reference can be made to Carbopol© 974P, 934P and 971 P.
Among the maleic anhydride-alkenyl derivative copolymers, preference is given to EMA© (Monsanto), which are straight-chain or crosslinked ethylene-maleic anhydride copolymers and they are e.g. crosslinked by divinyl ether. Reference can be made to J. Fields et al., Nature 186: 778-780, June 4, 1960.
With regards to their structure, the acrylic or methacrylic acid polymers and EMA© are preferably formed by basic units having the following formula: in which: - and R2, which can be the same or different, represent H or CH3 - x = 0 or , preferably x = 1 - y = 1 or 2, with x + y = 2.
For EMA©, x = 0 and y = 2 and for carbomers x = y = 1.
These polymers are dissolved in water or physiological salt solution (20 g/i NaCI) and the pH is adjusted to 7.3 to 7.4 by soda, in order to give the adjuvant solution in which the expression vectors will be incorporated.
The polymer concentration in the final vaccine composition can range between 0.01 and .5% w/v, more particularly 0.05 to 1 % w/v and preferably 0.1 to 0.4% w/v.
The cationic lipids (4) containing a quaternary ammonium salt and which are particularly but not exclusively suitable for plasmids, are preferably those complying with the following formula: in which Ri is a saturated or unsaturated straight-chain aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms and X is an amine or hydroxyl group.
Among these cationic lipids, preference is given to DMRIE (N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1 -propane ammonium ; WO-A-96/34109), preferably associated with a neutral lipid, preferably DOPE (dioleoyl-phosphatidyl-ethanol amine; Behr J. P., 1994, Bioconjugate Chemistry, 5, 382-389) in order to form DMRIE-DOPE.
Preferably, the plasmid mixture with said adjuvant is formed extemporaneously and preferably, prior to its administration, the mixture formed in this way is given time to complex, e.g. for between 10 and 60 minutes and in particular approximately 30 minutes.
When DOPE is present, the DMRIE:DOPE molar ratio is preferably 95:5 to 5:95, more particularly 1 :1.
The DMRIE or DMRIE-DOPE adjuvant:plasmid weight ratio is between 50:1 and 1 :10, particularly 10:1 and 1 :5 and preferably 1 :1 and 1 :2.
The cytokin or cytokine (5) can be supplied in protein form to the composition or vaccine, or can be co-expressed in the host with the immunogen or immunogens. Preference is given to the co-expression of the cytokin or cytokins, either by the same vector as that expressing the immunogen, or by its own vector.
The cytokins can in particular be chosen from among: interleukin 18 (IL-18), interleukin 12 (IL-12), interleukin 15 (IL- 5), MIP-1oc (macrophage inflammatory protein 1a; Marshall E. et al., Br. J. Cancer, 1997, 75 (12), 1715-1720), GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor). Particular reference is made to avian cytokins, particularly those of the chicken, such as clL-18 (Schneider K. et al., J. Interferon Cytokine Res., 2000, 20 (10), 879-883), clL-15 (Xin K. -Q. et al., Vaccine, 1999, 17, 858-866), and equine cytokins, particularly equine GM-CSF (WO-A-00/77210). Preferably, use is made of cytokins of the species to be vaccinated.
WO-A-00/77210 describes the nucleotide sequence and the amino acid sequence corresponding to equine GM-CSF, the in vitro GM-CSF production and the construction of vectors (plasmids and viral vectors) permitting the in vivo equine GM-CSF expression. These proteins, plasmids and viral vectors can be used in immunogenic compositions and equine vaccines according to the invention. For example, use can be made of the plasmid pJP097 described, in example 3 of said earlier-dated application or use can be made of the teaching of the latter in order to produce other vectors or for the in vitro production of equine GM-CSF and the incorporation of said vectors or said equine GM-CSF in immunogenic compositions or equine vaccines according to the invention.
The present invention also relates to immunogenic compositions and so-called subunit vaccines, incorporating the protein E and optionally one or more other proteins of the WN virus, particularly prM or M and preferably produced by in vitro expression in the manner described hereinbefore, as well as a pharmaceutically acceptable vehicle or excipient.
The pharmaceutically acceptable vehicles or excipients are known to the one skilled in the art and can e.g. be 0.9% NaCI saline solution or phosphate buffer.
The immunogenic compositions and subunit vaccines according to the invention preferably comprise one or more adjuvants, particularly chosen from among conventional adjuvants. Particularly suitable within the scope of the present invention are (1 ) an acrylic or methacryiic acid polymer, a maleic anhydride and alkenyl derivative polymer, (2) an immunostimulating sequence (ISS), particularly an oligodeoxyribonucleotide sequence having one or more non-methylated CpG units (Klinman D. . et al., Proc. Natl. Acad. Sci. USA, 1996, 93, 2879-2883; WO-A1 -98/16247), (3) an oil in water emulsion, particularly the emulsion SPT described on p 147 of "Vaccine Design, The Subunit and Adjuvant Approach", published by M. Powell, M. Newmann, Plenum Press 1995, and the emulsion MF59 described on p 183 of the same work, (4) a water in oil emulsion (EP-A-639 071 ), (5) saponin, particularly Quil-A, or (6) alumina hydroxide or an equivalent. The different types of adjuvants defined under 1 ), 2) and 3) have been described in greater detail hereinbefore in connection with the expression vector-based vaccines.
The doses and dose volumes are defined hereinafter in connection with the general description of immunization and vaccination methods.
According to the invention, the vaccination against the WN virus can be combined with other vaccinations within the framework of vaccination programs, in the form of immunization or vaccination kits or in the form of immunogenic compositions and multivalent vaccines, i.e. comprising at least one vaccine component • against the WN virus and at least one vaccine component against at least one other pathogenic agent. This also includes the expression by the same expression vector of genes of at least two pathogenic agents, including the WN virus.
The invention also relates to a multivalent immunogenic composition or a multivalent vaccine against the WN virus and against at least one other pathogen of the target species, using the same in vivo expression vector containing and expressing at least one polynucleotide of the WN virus according to the invention and at least one polynucleotide expressing an immunogen of another pathogen.
The thus expressed "immunogen" is understood to mean a protein, glycoprotein, polypeptide, peptide, epitope or derivative, e.g. fusion protein, inducing an immune response, preferably of a protective nature.
As was stated hereinbefore, these multivalent compositions or vaccines also comprise a pharmaceutically acceptable vehicle or excipient, and optionally an adjuvant.
The invention also relates to a multivalent immunogenic composition or a multivalent vaccine comprising at least one in vivo expression vector in which at least one polynucleotide of the WN virus is inserted and at least a second expression vector in which a polynucleotide encoding an immunogen of another pathogenic agent is inserted. As stated before, those multivalent compositions or vaccines also comprise a pharmaceutically acceptable vehicle or excipient, and optionally an adjuvant.
For the immunogenic compositions and multivalent vaccines, the other equine pathogens are more particularly chosen from among the group including viruses of equine rhinopneumonia EHV-1 and/or EHV-4 (and preferably there is a combination of immunogens of EHV-1 and EHV-4), equine influenza virus EIV, eastern encephalitis virus EEV, western encephalitis virus WEV, Venezuelan encephalitis virus VEV (preference is given to a combination of the three EEV, WEV and VEV), Clostridium tetani (tetanus) and their mixtures. Preferably, for EHV a choice is made of the genes gB and/or gD; for EIV the genes HA, NP and/or N; for viruses of encephalitis. C and/or E2; and for Clostridium tetani the gene encoding all or part of the subunit C of the tetanic toxin. This includes the use of polynucleotides encoding an immunologically active fragment or an epitope of said immunogen.
The other avian pathogens are more particularly chosen from among the group including viruses of the Marek's disease virus MDV (serotypes 1 and 2, preferably 1 ), Newcastle disease virus NDV, Gumboro disease virus IBDV, infectious bronchitis virus IBV, infectious anaemia virus CAV, infectious laryngotracheitis virus ILTV, encephalomyelitis virus AEV (or avian leukosis virus ALV), virus of hemorragic enteritis of turkeys (HEV), pneumovirosis virus (TRTV), fowj plague virus (avian influenza), chicken hydropericarditis virus, avian reoviruses, Escherichia coli, Mycoplasma gallinarum, Mycoplasma gallisepticum, Haemophilus avium, Pasteurella gallinarum, Pasteurella multocida gallicida, and mixtures thereof. Preferably, for MDV a choice is made of the genes gB and/or gD, for NDV the genes HN and/or P; for IBDV the gene VP2; for IBV the genes S (more particularly S1 ), M and/or N; for CAV the genes VP1 and/or VP2; for ILTV the genes gB and/or gD; for AEV the genes env and/or gag/pro; for HEV the genes 100K and hexon; for TRTV the genes F and/or G and for fowl plague the genes HA, N and/or NP. This includes the use of polynucleotides encoding an immunologically active fragment or an epitope of said immunogen.
By way of example, in a multivalent immunogenic composition or a multivalent vaccine according to the invention, to which an adjuvant has optionally been added in the manner described hereinbefore and which is intended for the equine species, it is possible to incorporate orie or more of the plasmids described in WO-A-98/03198 and particularly in examples 8 to 25 thereof, and those described in WO-A-00/77043 and which relate to the equine species, particularly those described in examples 6 and 7 thereof. For the avian species, it is e.g. possible to incorporate one or more of the plasmids described in WO-A1 -98/03659, particularly in examples 7 to 27 thereof.
The immunogenic compositions or recombinant vaccines as described hereinbefore can also be combined with at least one conventional vaccine (inactivated, live attenuated, subunits) directed against at least one other pathogen.
In the same way, the immunogenic compositions and subunit vaccines according to the invention can form the object of combined vaccination. Thus, the invention also relates to multivalent immunogenic compositions and multivalent vaccines comprising one or more proteins according to the invention and one or more immunogens (the term immunogen having been defined hereinbefore) of at least one other pathogenic agent (particularly from among the above list) and/or another pathogenic agent in inactivated or attenuated form. In the manner described hereinbefore, these multivalent vaccines or compositions also incorporate a pharmaceutically acceptable vehicle or excipient and optionally an adjuvant.
The present invention also relates to methods for the immunization and vaccination of the target species referred to hereinbefore.
These methods comprise the administration of an effective quantity of an immunogenic composition or vaccine according to the invention. This administration can more particularly take place by the parenteral route, e.g. by subcutaneous, intradermic or intramuscular administration, or by oral and/or nasal routes. One or more administrations can take place, particularly two administrations.
The different vaccines can be injected by a needleless, liquid jet injector. For plasmids it is also possible to use gold particles coated with plasmid and ejected in such a way as to penetrate the cells of the skin of the subject to be immunized (Tang et al., Nature 1992, 356, 152-154).
The immunogenic compositions and vaccines according to the invention comprise an effective expression vector or polypeptide quantity.
In the case of immunogenic compositions or vaccines based on plasmid, a dose consists in general terms about in 10 ς to about 2000 μg1 particularly about 50 μg to about 000 μg. The dose volumes can be between 0.1. and 2 ml, preferably between 0.2 and 1 ml.
These doses and dose volumes are suitable for the vaccination of equines and mammals.
For the vaccination of the avian species, a dose is more particularly between about 10 μg and about 500 μg and preferably between about 50 g and about 200 μg. The dose volumes can in particular be between 0.1 and 1 ml, preferably between 0.2 and 0.5 ml.
The one skilled in the art has the necessary skill to optimize the effective plasmid dose to be used for each immunization or vaccination protocol and for defining the optimum administration route.
In the case of immunogenic compositions or vaccines based on poxviruses, a dose is in general terms between about 102 pfu and about 109 pfu.
For the equine species and mammals, when the vector is the vaccinia virus, the dose is more particularly between about 104 pfu and about 109 pfu, preferably between about 106 pfu and about 108 pfu and when the vector is the canarypox virus, the dose is more particularly between about 105 pfu and about 109 pfu and preferably between about 105,5 pfu or 106 pfu and about 108 pfu.
For the avian species, when the vector is the canarypox virus, the dose is more particularly between about 103 pfu and about 107 pfu, preferably between about 104 pfu and about 106 pfu and when the vector is the fowlpox virus, the dose is more particularly between about 102 pfu and about 105 pfu, preferably between about 103 pfu and about 10s pfu.
In the case of immunogenic compositions or vaccines based on the viral vector other than poxviruses, particularly herpes viruses, a dose is generally between about 103 pfu and about 108 pfu. In the case of immunogenic compositions or avian vaccines a dose is generally between about 103 pfu and about 106 pfu. In the case of immunogenic compositions or equine vaccines a dose is generally between about 106 pfu and about 108 pfu.
The dose volumes of the immunogenic compositions and equine vaccines based on viral vectors are generally between 0.5 and 2.0 ml, preferably between 1.0 and 2.0 ml, preferably 1.0 ml. The dose volumes of immunogenic compositions and avian vaccines based on viral vectors are generally between 0.1 and .0 ml, preferably between 0.1 and 0.5 ml and more particularly between 0.2 and 0.3 ml. Also in connection with such a vaccine, the one skilled in the art has the necessary competence to optimise the number of administrations, the administration route and the doses to be used for each immunization protocol. In particular, there are two administrations in the horse, e.g. at 35 day intervals.
In the case of immunogenic compositions or subunit vaccines, a dose comprises in general terms about 10 μς to about 2000 μ9, particularly about 50 μg to approximately 1000 μg. The dose volumes of the immunogenic compositions and equine vaccines based on viral vectors are generally between 1.0 and 2.0 ml, preferably between 0.5 and 2.0 ml and more particularly 1.0 ml. The dose volumes of the immunogenic compositions and avian vaccines based on viral vectors are generally between 0.1 and 1 .0 ml, preferably between 0.1 and 0.5 ml, and more particularly between 0.2 and 0.3 ml. Also for such a vaccine, the one skilled in the art has the necessary skill to optimise the number of administrations, the administration route and the doses to be used for each immunization protocol.
The invention also relates to the use of an in vivo expression vector or a preparation of vectors or polypeptides according to the invention for the preparation of an immunogenic composition or a vaccine intended to protect target species against the WN virus and possibly against at least one other pathogenic agent. The different characteristics indicated in the description are applicable to this object of the invention.
A vaccine based on plasmid or a viral vaccine expressing one or more proteins of the WN virus or a WN subunit vaccine according to the present invention will not induce in the vaccinated animal the production of antibodies against other proteins of said virus, which are not represented in the immunogenic composition or vaccine. This feature can be used for the development of differential diagnostic methods making it possible to make a distinction between animals infected by the WN pathogenic virus and animals vaccinated with vaccines according to the invention. In the former, these proteins and/or antibodies directed against them are present and can be detected by an antigen-antibody reaction. This is not the case with the animals vaccinated according to the invention, which remain negative. In order to bring about this discrimination, use is made of a protein which is not represented in the vaccine (not present or not expressed), e.g. protein C or protein NS1 , NS2A, NS2B or NS3 when it is not represented in the vaccine.
Thus, the present invention relates to the use of vectors, preparations and polypeptides according to the invention for the preparation of immunogenic compositions and vaccines making it possible to discriminate between vaccinated animals and infected animals.
It also relates to an immunization and vaccination method associated with a diagnostic method permitting such a discrimination.
The protein selected for the diagnosis or one of its fragments or epitopes is used as the antigen in the diagnostic test and/or is used for producing polyclonal or monoclonal antibodies. The one skilled in the art has sufficient practical knowledge to produce these antibodies and to implement antigens and/or antibodies in conventional diagnostic methods, e.g. ELISA tests.
The invention will now be described in greater detail using embodiments considered as non-limitative examples.
Examples All the constructions are implemented using standard molecular biology methods (cloning, digestion by restriction enzymes, synthesis of a complementary single-strand DNA, polymerase chain reaction, elongation of an oligonucleotide by DNA polymerase...) described by Sambrook J. et al. (Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor. New York, 1989). All the restriction fragments used for the present invention, as well as the various polymerase chain reaction (PCR) are isolated and purified using the Geneclean© kit (B1O101 Inc. La Jolla, CA).
Example 1 : Culture of the West Nile fever virus For their amplification, West Nile fever viruses NY99 (Lanciotti R. S. et al., Science, 1999, 286, 2333-7)) are cultured on VERO cells (monkey renal cells), obtainable from the American Type Culture Collection (ATCC) under no. CCL-81.
The VERO cells are cultured in 25 cm2 Falcon with eagle-MEM medium supplemented by 1 % yeast extracts and 10% calf serum containing approximately 100,000 cells/ml. The cells are cultured at +37°C under a 5% C02 atmosphere.
After three days the cellular layer reaches to confluence. The culture medium is then replaced by the eagle-MEM medium supplemented by 1 % yeast extracts and 0.1 % cattle serum albumin and the West Nile fever virus is added at a rate of 5 pfu/cell.
When the cytopathogenic effect (CPE) is complete (generally 48 to 72 hours after the start of culturing), the viral suspensions are harvested and then clarified by centrifugation and frozen at -70°C. In general, three to four successive passages are necessary for producing a viral batch, which is stored at -70°C.
Example 2: Extraction of viral RNA from the West Nile fever virus The viral RNA contained in 100 ml of viral suspension of the West Nile fever virus strain NY99 is extracted after thawing with solutions of the High Pure Viral RNA Kit Cat # 1 858 882, Roche Molecular Biochemicals, whilst following the instructions of the supplier for the extraction stages. The RNA sediment obtained at the end of extraction is resuspended with 1 to 2 ml of RNase-free, sterile distilled water.
Example 3: Construction of plasmid pFC 101 The complementary DNA (ADNC) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions supplied by the manufacture.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) is carried out with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: CF101 (30 mer) (SEQ ID NO:1) 5Ί I I I I I GAATTCGTTACCCTCTCTAACTTC 3' and FC102 (33 mer) (SEQ ID NO:2) 5Ί I I I I I I CTAGATTACCTCCGACTGCGTCTTGA 3' This pair of oligonucleotides allows the incorporation of an EcoRI restriction site, a Xbal restriction site and a stop codon at 3' of the insert.
The synthesis of the first DNAc strand takes place by elongation of oligonucleotide FC102, following the hybridization of the latter with the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The conditions of the PCR reaction in the presence of the pair of oligonucleotides FC101 and FC102 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, then 62°C for 1 min and 72°C for 2 min) and finally 72°C for 7 min to produce a 302 bp fragment.
This fragment is digested by EcoRI and then by Xbal in order to isolate, following agarose gel electrophoresis, the approximately 290 bp EcoRI-Xbal fragment, which is called fragment A.
The pVR1020 eukaryote expression plasmid (C. J. Luke et al. of Infectious Diseases, 1997, 175, 95-97) derived from the plasmid pVR1012 (fig. 1 and example 7 of WO-A-98/03199 - Hartikka J. et al., 1997, Human Gene Therapy, 7, 1205-1217), contains the frame encoding the signal sequence of the human tissue plasminogen activator (tP A).
A pVR1020 plasmid is modified by BamHI-Bglll digestion and insertion of a sequence containing several cloning sites (BamHI, NotI, EcoRI, Xbal, Pmll, PstI, Bglll) and resulting from the hybridization of the following oligonucleotides.
BP326 (40 mer) (SEQ ID NO: 3) 5'GATCTGCAGCACGTGTCTTAGAGGATATCGAATTCGCGGCC 3' and BP329 (40 mer) (SEQ ID No: 4) 5'GATCCGCGGCCGCGAATTCGATATCCTCTAGACACGTGCT 3' The thus obtained vector with a size of approximately 5105 base pairs (or bp) is called pAB110.
Fragment A is ligatured with the pAB110 expression plasmid previously digested by Xbal and EcoRI, in order to give the plasmid pFC101 (5376 bp). Under the control of the early promoter of human cytomegalovirus or hCMV-IE (human Cytomegalovirus Immediate Early), said plasmid contains an insert encoding the signal sequence of the activator of tPA followed by the sequence encoding the protein prM.
Example 4: Construction of plasmid pFC102 The complementary DNA (DNAc) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) takes place with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: FC103 (30 mer) (SEQ ID NO: 5) 5Ί I I I I I GAATTCTCACTGACAGTGCAGACA 3" and FC104 (33 mer) (SEQ ID NO: 6) 5' I I I I I I I CTAGATTAGCTGTAAGCTGGGGCCAC 3' This pair of oligonucleotides allows the incorporation of an EcoRI restriction site and a Xbal restriction site and a stop codon at 3' of the insert.
The first DNAc strand is synthesized by elongation of oligonucleotide FC104, following the hybridization of the latter on the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The conditions of the PCR reaction in the presence of the pair of oligonucleotides FC103 and FC104 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, then 62°C for 1 min and 72°C for 2 min) and finally 72°C for 7 min to produce a 252 bp fragment.
This fragment is digested by EcoRI and then Xbal in order to isolate, following agarose gel electrophoresis, the approximately 240 bp EcoRI-Xbal fragment. This fragment is ligatured with the pAB110 expression plasmid (example 3) previously digested by Xbal and EcoRI in order to give the plasmid pFC102 (5326 bp). Under the control of the early human cytomegalovirus or hCMV-IE (human Cytomegalovirus Immediate Early) promoter, this plasmid contains an insert encoding the signal sequence of the activator of tPA, followed by the sequence encoding the protein M.
Example 5: Construction of plasmid pFC103 The complementary DN A (DNAc) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) takes place with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: FC105 (30 mer) (SEQ ID NO: 7) 5' I I I I I I GAATTCTTCAACTGCCTTGGAATG 3' and FC106 (33 mer) (SEQ ID NO: 8) 5' I I I I I I I CTAGATTAAGCGTGCACGTTCACGGA 3'.
This pair of oligonucleotides allows the incorporation of an EcoRI restriction site and a Xbal restriction site, together with a stop codon at 3' of the insert.
The synthesis of the first DNAc strand takes place by elongation of oligonucleotide FC106, following its hybridization with the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The PCR reaction conditions in the presence of the pair of oligonucleotides FC105 and FC106 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, then 62°C for 1 min and 72°C for 2 min), and finally 72°C for 7 min for producing a 1530 bp fragment.
This fragment is digested by EcoRI and then by Xbal in order to isolate, following agarose gel electrophoresis, the approximately 1518 bp EcorRI-Xbal fragment. This fragment is ligatured with the pAB 110 expression plasmid (example 3) previously digested by Xbal and EcoRI in order to give the plasmid pFC103 (6604 bp). Under the control of the early promoter of human cytomegalovirus or hCMV-IE (human Cytomegalovirus Immediate Early), said plasmid contains an insert encoding the signal sequence of the activator of tPA, followed by the sequence encoding the protein E.
Example 6: Construction of plasmid pFC104 The complementary DNA (DNAc) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) takes place with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: FC101 (30 mer) (SEQ ID NO :1 ) and FC106 (33 mer) (SEQ ID NO :8) This pair of oligonucleotides allows the incorporation of an EcoRI restriction site, a Xbal restriction site and a stop codon at 3' of the insert Synthesis of the first DNAc strand takes place by elongation of oligonucleotide FC106, following its hybridization with the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The PCR reaction conditions in the presence of the pair of oligonucleotides FC101 and FC106 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, then 62°C for 1 min and 72°C for 2 min) and finally 72°C for 7 min in order to produce a 2031 bp fragment.
This fragment is digested by EcoRI and then Xbal in order to isolate, following agarose gel electrophoresis, the approximately 2019 bp EcoRI-Xbal fragment. This fragment is ligatured with the pAB110 expression plasmid (example 3), previously digested by Xbal and EcoRI in order to give the pFC104 plasmid (7105 bp). Under the control of the early human cytomegalovirus promoter or hCMV-IE (human Cytomegalovirus Immediate Early), said plasmid contains an insert encoding the signal sequence of the activator of tPA, followed by the sequence encoding the protein prM-M-E.
Example 7: Construction of plasmid pFC105 The complementary DNA (DNAc) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) takes place with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: CF107 (36 mer) (SEQ ID NO :9) 5" I I I I I I GATATCACCGGAATTGCAGTCATGATTGGC 3' and FC106 (33 mer) (SEQ ID NO :8).
This pair of oligonucleotides allows the incorporation of an EcoRV restriction site, a Xbal restriction site and a stop codon at 3' of the insert.
Synthesis of the first DNAc strand takes place by elongation of the FC106 oligonucleotide, following its hybridization with the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The PCR reaction conditions in the presence of the pair of oligonucleotides FC106 and FC107 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, then 62°C for 1 min and 72°C for 2 min) and finally 72°C for 7 min in order td produce a 2076 bp fragment.
This fragment is digested by EcoRV and then Xbal in order to isolate, following agarose gel electrophoresis, the approximately 2058 bp EcoRV-Xbal fragment.
This fragment is ligatured with the pVR1012 expression plasmid, previously digested by Xbal and EcoRV, in order to give the plasmid pFC105 (6953 bp). Under the control of the early human cytomegalovirus promoter or hCMV-IE (human Cytomegalovirus Immediate Early), this plasmid contains an insert encoding the polyprotein prM-M-E.
Example 8: Construction of plasmid pFC106 The complementary DNA (DNAc) of the West Nile fever virus NY99 is synthesized with the Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) takes place with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: FC108 (36 mer) (SEQ ID NO :10) 5Ί I I I I I GATATCATGTATAATGCTGATATGATTGAC 3' and FC109 (36 mer) (SEQ ID NO :11 ) 5Ί I I I I I I CTAGATTAACGTTTTCCCGAGGCGAAGTC 3' This pair of oligonucleotides allows the incorporation of an EcoRV restriction site, a Xbal restriction site, an initiating ATG codon in 5' and a stop codon at 3' of the insert.
Synthesis of the first DNAc strand takes place by elongation of the oligonucleotide FC109, following its hybridization with the RNA matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The PCR reaction conditions in. the presence of the pair of nucleotides FC108 and FC109 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, 62°C for 1 min and then 72°C for 2 min) and finally 72°C for 7 min to produce a 2973 bp fragment.
This fragment is digested by EcoRV and then Xbal in order to isolate, following agarose gel electrophoresis, the approximately 2955 bp EcoRV-Xbal fragment.
This fragment is ligatured with the pVR 1012 expression plasmid previously digested by Xbal and EcoRV in order to give the plasmid pFC106 (7850 bp). Under the control of the early human cytomegalovirus promoter or hCMV-IE (human Cytomegalovirus Immediate Early), this plasmid contains an insert encoding the polyprotein NS2A-NS2B-NS3.
Example 9: Construction of the donor plasmid for insertion in site C5 of the ALVAC canarypox virus Fig. 16 of US patent 5,756, 03 shows the sequence of a genomic DNA 3199 bp fragment of the canarypox virus. Analysis of this sequence has revealed an open reading frame (ORF) called C5L, which starts at position 1538 and ends at position 1859. The construction of an insertion plasmid leading to the deletion of the ORF C5L and its replacement by a multiple cloning site flanked by transcription and translation stop signals was implemented in the following way.
A PCR reaction was performed on the basis of the matrix constituted by genomic DNA of the canarypox virus and with the following oligonucleotides: C5A1 (42 mer) (SEQ ID NO :12): 5'ATCATCGAGCTCCAGCTGTAATTCATGGTCGAAAAGAAGTGC 3' and C5B1 (73 mer) (SEQ ID NO :13): 5OAATTCCTCGAGCTGCAGCCCGGGTTTTTATAGCTMTTAGTCATTTTTTGAGAGTACCACTTCAGCTA CCTC 3' in order to isolate a 223 bp PCR fragment (fragment B). 24 A PCR reaction was carried out on the basis of the matrix constituted by genomic DNA of the canarypox virus and with the following oligonucleotides: C5C1 (72 mer) (SEQ ID NO :14): 5'CCCGGGCTGCAGCTCGAGGAATTC I I I I I ATTGATTAACTAGTCATTATAAAGATCTAAAATGCATAAT TTC 3' and C5D1 (45 mer) (SEQ ID NO :15): 5'GATGATGGTACCGTAAACAAATATAATGAAAAGTATTCTAAACTA 3' in order to isolate a 482 bp PCR fragment (fragment C).
Fragments B and C were hybridized together in order to serve as a matrix for a PCR reaction performed with the oligonucleotides C5A1 (SEQ ID NO :12) and C5D1 (SEQ ID NO :15) in order to generate a 681 bp PCR fragment. This fragment was digested by the restriction enzymes Sacl and Kpnl in order to isolate, following agarose gel electrophoresis, a 664 bp Sacl-Kpnl fragment. This fragment was ligatured with the bplueScript© II SK+ vector (Stratagene, La Jolla, USA, Cat # 212205), previously digested by the restriction enzymes Sacl and Kpnl, in order to give the plasmid pC5L The sequence of this plasmid was verified by sequencing. This plasmid contains 166 bp of sequences upstream of ORF C5L (left flanking arm C5), an early transcription stop vaccine signal, stop codons in 6 reading frames, a multiple cloning site containing restriction sites Smal, Pstl, Xhol and EcoRI and finally 425 bp of sequences located downstream of ORF C5L (right flanking arm C5).
The plasmid pMP528HRH (Perkus M. et al. J. Virol. 1989, 63, 3829-3836) was used as the matrix for amplifying the complete sequence of the vaccine promoter H6 (GenBank access no. M28351 ) with the following oligonucleotides: JCA291 (34 mer) (SEQ ID NO :16) 5,AAACCCGGGTTCTTTATTCTATACTTAAAAAGTG 3■ and JCA292 (43 mer) (SEQ ID NO :17) 5'AAAAGAATTCGTCGACTACGATACAAACTTAACGGATATCGCG 3' in order to amplify a 149 bp PCR fragment. This fragment was digested by restriction enzymes Smal and EcoRI in order to isolate, following agarose gel electrophoresis, a 138 bp Smal-EcoRI restriction fragment. This fragment was then ligatured with the plasmid pC5L, previously digested by Smal and EcoRI, in order to give the plasmid pFC107.
Example 10: Construction of the recombinant virus vCP1712 A PCR reaction was performed using the plasmid pFC105 (example 7) as the matrix and the following oligonucleotides: FC110 (33 mer (SEQ ID NO : 18): 5'TTTTCGCGAACCGGAATTGCAGTCATGATTGGC 3' and FC1 1 (39 mer) (SEQ ID NO : 19): 5'TTTTGTCGACGCGGCCGCTTAAGCGTGCACGTTCACGGA 3' in order to amplify an approximately 2079 bp PCR fragment. This fragment was digested by restriction enzymes Nrul and Sail in order to isolate, following agarose gel electrophoresis, an approximately 2068 bp Nrul-Sall restriction fragment. This fragment was then ligatured with plasmid pFC107 (example 9) previously digested by restriction enzymes Nrul and Sail in order to give the plasmid pFC108.
Plasmid pFC108 was linearized by Notl, then transfected in primary chicken embryo cells infected with the canarypox virus (ALVAC strain) according to the previously described calcium phosphate precipitation method (Panicali et Paoletti Proc. Nat. Acad. Sci. 1982, 79, 4927-4931 ; Piccini et al. In Methods in Enzymology, 1987, 53, 545-563, publishers Wu R. and Grossman L. Academic Press). Positive plaques were selected on the basis of a hybridization with a radioactively labelled probe specific to the nucleotide sequence of the envelope glycoprotein E. These plaques underwent 4 successive selection/purification cycles until a pure population was isolated. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC108 and the genome of the ALVAC canarypox virus was then amplified and the recombinant virus stock obtained was designated VCP1712.
Example 11 : Construction of the recombinant virus vCP1713 Plasmid pFC104 (example 6) was digested by the restriction enzyme Sail and Pmll in order to isolate, following agarose gel electrophoresis, an approximately 2213 bp Pmll-Sall restriction fragment. This fragment was ligatured with plasmid pFC107 (example 9) previously digested by the Nrul and Sail restriction enzymes in order to give the plasmid pFC109.
Plasmid pFC109 was linearized by Notl, then transfected in primary chicken embryo cells infected with the canarypox virus (ALVAC strain) according to the method of example 10. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC109 and the genome of the ALVAC canarypox virus was selected on the basis of a hybridization of a radioactively labelled probe specific to the nucleotide sequence of the envelope glycoprotein E and was then amplified. The recombinant virus stock obtained was designated vCP1713.
Example 12: Construction of the recombinant virus vCP1714 Plasmid pFC103 (example 5) was digested by the Sail and Pmll restriction enzymes in order to isolate, following agarose gel electrophoresis, an approximately 1712 bp Pmll-Sall restriction fragment. This fragment was ligatured with the plasmid pFC107 (example 9) previously digested by the Nrul and Sail restriction enzymes in order to give the plasmid pFC1 10.
Plasmid pFC1 10 was linearized by Notl, then transfected in primary chicken embryo cells infected with the canarypox virus (ALVAC strain) according to the method of example 10. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC1 10 and the genome of the ALVAC canarypox virus was selected on the basis of a hybridization with a radioactively labelled probe specific to the nucleotide sequence of the envelope glycoprotein E and was then amplified. The recombinant virus stock obtained was then designated vCP1714.
Example 13: Construction of the recombinant virus vCP1715 Plasmid pFC102 (example 4) was digested by the Sail and Pmll restriction enzymes in order to isolate, following agarose gel electrophoresis, an approximately 434 bp Pmll-Sall restriction fragment. This fragment was ligatured with the plasmid pFC107 (example 9) previously digested by the Nrul and Sail restriction enzymes to give the plasmid pFC1 11 .
Plasmid pFC11 1 was linearized by Notl, then transfected in primary chicken embryo cells infected with the canarypox virus (ALVAC strain) according to the method of example 10. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC1 11 and the genome of the ALVAC canarypox virus was selected on the basis of hybridization with a radioactiveiy labelled probe specific to the nucleotide sequence of the membrane M glycoprotein and was then amplified. The recombinant virus stock obtained was designated vCP1715.
Example 14: Construction of the recombinant virus vCP1716 Plasmid pFC101 (example 3) is digested by the Sail and Pmll restriction enzymes in order to isolate, following agarose gel electrophoresis, an approximately 484 bp Pmll-Sall restriction fragment. This fragment is ligatured with the plasmid pFC107 (example 9) previously digested by the Nrul and Sail restriction enzymes to give the plasmid pFC112.
Plasmid pFC112 was linearized by Notl and then transfected in primary chicken embryo cells infected with the canarypox virus (ALVAC strain) according to the method of example 10. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC1 12- and the genome of the ALVAC canarypox virus was selected on the basis of a hybridization with a radioactiveiy labelled probe specific to the nucleotide sequence of the pre-membrane prM glycoprotein and was then amplified. The recombinant virus stock obtained was designated vCP1716.
Example 15: Construction of the donor plasmid for insertion in site C6 of the ALVAC canarypox virus Fig. 4 of WO-A-01/05934 shows the sequence of a 3700 bp genomic D A fragment of the canarypox virus. Analysis of this sequence revealed an open reading frame (ORF) called C6L, which starts at position 377 and ends at position 2254. The construction of an insertion plasmid leading to the deletion of the ORF C6L and its replacement by a multiple cloning site flanked by. transcription and translation stop signals was implemented in the following way.
A PCR reaction was performed on the basis of the matrix constituted by the genomic DNA of the canarypox virus and with the following oligonucleotides: C6A1 (42 mer) (SEQ ID NO :20): 5'ATCATCGAGCTCGCGGCCGCCTATCAAAAGTCTTAATGAGTT 3* and C6B1 (73 mer) (SEQ ID NO :21 ): 5'GAATTCCTCGAGCTGCAGCCCGGG I I I I I ATAGCTMTTAGTCATTTTTTCGT GTMGTATTTTTATT TAA 3' to isolate a 432 bp PCR fragment (fragment D).
A PCR reaction was performed on the basis of the matrix constituted by the genomic DNA of the canarypox virus and with the following oligonucleotides: C6C1 (72 mer) (SEQ ID NO :22): 5OCCGGGCTGCAGCTCGAGGAATTCTTTTTATTGATTAACTAGTCAAATGAGTATATATMTTGAAAAAG TAA 3' and C6D1 (45 mer) (SEQ ID NO :23): 5OATGATGGTACCTTCATAAATACAAGTTTGATTAAACTTAAGTTG 3* to isolate a 1210 bp PCR fragment (fragment E).
Fragments D and E were hybridized together to serve as a matrix for a PCR reaction performed with the oligonucleotides C6A1 (SEQ ID NO :20) and C6D1 (SEQ ID NO :23) to generate a 1630 bp PCR fragment. This fragment was digested by the Sacl and Kpnl restriction enzymes to isolate, after agarose gel electrophoresis, a 1613 bp Sacl-Kpnl fragment. This fragment was ligatured with the bplueScript© II SK+ vector (Stratagene, La Jolla, CA, USA, Cat # 212205) previously digested by the Sacl and Kpnl restriction enzymes to give the plasmid pC6L The sequence of this plasmid was verified by sequencing. Said plasmid contains 370 bp of sequences upstream of ORF C6L (C6 left flanking arm), an early transcription stop vaccinia signal, stop codons in the six reading frames, a multiple cloning site containing the Smal, Pstl, Xhol and EcoRI restriction sites and finally 1156 bp of sequences downstream of the ORF C6L (C6 right flanking arm).
Plasmid pMPIVC (Schmitt J. F. C. et al., J. Virol., 1988, 62, 1889-1897, Saiki R. K. et al., Science, 1988, 239, 487-491 ) was used as the matrix for amplifying the complete sequence of the I3L vaccine promoter with the following oligonucleotides: FC112 (33 mer) (SEQ ID NO :24): 5'AAACCCGGGCGGTGGTTTGCGATTCCGAAATCT 3' and FC113 (43 mer) (SEQ ID NO :25): 5'AAAAGAATTCGGATCCGATTAAACCTAAATAATTGTACTTTGT 3" to amplify a 151 bp PCR fragment. This fragment was digested by the Smal and EcoRI restriction enzymes in order to isolate, following agarose gel electrophoresis, an approximately 136 bp Smal-EcoRI restriction fragment. This fragment was then ligatured with plasmid pC6L previously digested by Smal and EcoRI to give the plasmid pFC113.
Example 16: Construction of recombinant viruses vCP1717 and VCP1718 A PCR reaction was performed using the plasmid pFC106 (example 8) as the matrix and the following oligonucleotides: FC1 14 (33 mer) (SEQ ID NO :26): 5'TTTCACGTGATGTATAATGCTGATATGATTGAC 3' and FC1 15 (42 mer) (SEQ ID NO :27): - 5'TTTTGGATCCGCGGCCGCTTAACGTrTTCCCGAGGCGAAGTC 3' to amplify an approximately 2973 bp PCR fragment. This fragment was digested with the Pmll and BamHI restriction enzymes to isolate, following agarose gel electrophoresis, the approximately 2958 bp Pmll-BamHl restriction fragment (fragment F). Plasmid pFC113 (example 15) was digested by the Pmll and BamHI restriction enzymes to isolate, following agarose gel electrophoresis, the approximately 4500 bp Pmll-BamHl restriction fragment (fragment G). Fragments F and G were then ligatured together to give the plasmid pFC1 14.
Plasmid pFC114 was linearized by Notl, then transfected in primary chicken embryo cells infected with canarypox virus vCP1713 (example 11 ) according to the previously described calcium phosphate precipitation method (Panicali et Paoletti Proc. Nat. Acad. Sci. 1982, 79, 4927-4931 ; Piccini et al. In Methods in Enzymology, 1987, 53, 545-563, publishers Wu R. and Grossman L. Academic Press). Positive plaques were selected on the basis of a hybridization with a radioactively labelled probe specific to the nucleotide sequence of envelope glycoprotein E. These ranges underwent four successive selection/purification cycles of the ranges until a pure population was isolated. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC1 14 and the genome of the ALVAC canarypox virus was then amplified and the recombinant virus stock obtained was designated vCP1717, The Notl-linearized pFC1 14 plasmid was also used for transfecting primary chicken embryo cells infected with the vCP1712 canarypox virus (example 10) using the procedure described hereinbefore. The thus obtained recombinant virus stock was designated vCP 718.
Example 17: Construction of plasmid pFC115 The complementary DNA (DNAc) of the West Nile fever virus NY99 was synthesized with Gene Amp RNA PCR Kit (Cat # N 808 0017, Perkin-Elmer, Norwalk, CT 06859, USA) using the conditions provided by the supplier.
A reverse transcriptase polymerase chain reaction (RT-PCR reaction) was carried out with 50 μΙ of viral RNA suspension of the West Nile fever virus NY99 (example 2) and with the following oligonucleotides: FC1 16 (39 mer) (SEQ ID NO :28) 5'TTTTTTG ATATC ATG ACC G G AATTG C AGTC ATG ATTG G C 3' and FC106 (33 mer) (SEQ ID NO :8).
This pair of oligonucleotides makes it possible to incorporate an EcoRV restriction site, a Xbal restriction site, an initiator code at 5' and a stop code at 3' of the insert.
Synthesis of the first DNAc strand takes place by elongation of the oligonucleotide FC106, following its hybridization with the RN A matrix.
The synthesis conditions of the first DNAc strand are a temperature of 42°C for 15 min, then 99°C for 5 min and finally 4°C for 5 min. The conditions of the PCR reaction in the presence of the pair of oligonucleotides FC106 and FC116 are a temperature of 95°C for 2 min, then 35 cycles (95°C for 1 min, 62°C for 1 min and then 72°C for 2 min) and finally 72°C for 7 min to produce a 2079 bp fragment.
This fragment is digested by EcoRV and then Xbal to isolate, following agarose gel electrophoresis, the approximately 2061 bp EcoRV-Xbal fragment.
This fragment is ligatured with the pVR1012 expression plasmid previously digested by Xbal and EcoRV to give the plasmid pFC115 (6956 bp). Under the control of the early human cytomegalovirus promoter or hCMV-IE (human Cytomegalovirus Immediate Early), this plasmid contains an insert encoding the polyprotein prM-M-E.
Example 18: Construction of the recombinant viruses vCP2017 A PCR reaction was carried out using the plasmid pFC1 15 (example 17) as the matrix and the following oligonucleotides: FC1 7 (36 mer) (SEQ ID NO :29): 5'TTTTCGCGAATGACCGGAATTGCAGTCATGATTGGC 3' and FC1 1 1 (39 mer) (SEQ ID NO :19) to amplify an approximately 2082 bp PCR fragment. This fragment was digested by Nrul and Sail restriction enzymes to isolate, after agarose gel electrophoresis, an approximately 2071 bp Nrl-Sall restriction fragment. This fragment was then ligatured with plasmid pFC107 (example 9) previously digested by the Nrul and Sail restriction enzymes to give the plasmid pFC1 16.
Plasmid pFC116 was linearized by Notl and then transfected in primary chicken embryo cells infected with canarypox virus (ALVAC strain) using the procedure of example 10. A representative plaque corresponding to in vitro recombination between the donor plasmid pFC1 16 and the genome of the ALVAC canarypox virus was selected on the basis of a hybridization with a radioactively labelled probe specific to the nucleotide sequence of the envelope glycoprotein E and was then amplified. The recombinant virus stock obtained was designed VCP2017.
Example 19: Production of recombinant vaccines For the preparation of equine vaccines, the recombinant canarypox vCP1712 virus (example 10) is adjuvanted with carbomer solutions, namely Carbopol™974P manufactured by BF Goodrich, Ohio, USA (molecular weight about 3,000,000).
A 1.5% Carbopol™974P stock solution is initially prepared in distilled water containing 1 g/l of sodium chloride. This stock solution is then used for the preparation of a 4 mg/ml Carbopol™974P solution in physiological salt solution. The stock solution is mixed with the adequate volume of said physiological salt solution, either in a single stage or in several successive stages, the pH value being adjusted in each stage with a 1 N sodium hydroxide solution (or even more concentrated) in order to obtain a final pH value of 7.3 to 7.4.
The ready-to-use Carbopol™974P solution obtained in this way is used for taking up recombinant, lyophilized viruses or for diluting concentrated, recombinant virus stock solutions. For example, to obtain a viral suspension containing 108 pfu/1 ml dose, a viral stock solution is diluted so as to obtain a titer of 108'3 pfu/ml, followed by dilution in equal parts with said ready-to-use 4 mg/ml Carbopol™974P solution.
Recombinant vaccines can also be produced with recombinant canarypox viruses vCP1713 (example 11 ) or vCP1717 (example 16) or vCP1718 (example 16) or vCP2017 (example .18) or a mixture of three canarypox viruses vCP1714 (example 12), vCP1715 (example 13) and vCP1716 (example 14) according to the procedure described hereinbefore.
Example 20: Production of DNA vaccines for equines An DNA solution containing the plasmid pFC104 (example 6) is concentrated by ethanolic precipitation in the manner described by Sambrook et al (1989). The DNA sediment is taken up by a 0.9% NaCI solution so as to obtain a concentration of 1 mg/ml. A 0.75 mM DMRIE-DOPE solution is prepared by taking up a DMRIE-DOPE lyophilizate by a suitable sterile H20 volume.
The formation of plasmid-lipid DNA complexes is brought about by diluting in equal parts the 0.75 mM DMRIE-DOPE solution (1 :1) with the 1 mg/ml DNA solution in 0.9% NaCI. The DNA solution is progressively introduced with the aid of a 26G crimped needle along the wall of the flask containing the cationic lipid solution so as to prevent the formation of foam. Gentle stirring takes place as soon as the two solutions have mixed. Finally a composition comprising 0.375 mM of DMRIE-DOPE and 500 μg/ml plasmid is obtained.
It is desirable for all the solutions used to be at ambient temperature for all the operations described hereinbefore. DNA/DMRIE-DOPE complexing takes place at ambient temperature for 30 minutes before immunizing the animals. 31 DNA vaccines can also be produced with DNA solutions containing plasmids pFC104 (example 6) and pFC106 (example 8) or containing plasmids pFC105 (example 7) and pFC106, plasmids pFC115 (example 17) and pFC106, or containing plasmid pFCIO , pFC102 and pFC 03 (examples 3 to 5), or containing plasmid pFC105 or pFC115 according to the procedure described in the present example.
Example 21 : In vitro expression tests The expression of WN proteins is tested for each construction by conventional indirect immunofluorescence and Western Blot methods.
These tests are carried out on 96 well plates containing CHO cells cultured in monolayers and transfected by plasmids or containing CEF cells cultured in monolayers and infected by recombinant viruses.
The WN proteins are detected by the use of infected chicken or horse sera and of labelled anti-sera.
The size of the fragments obtained after migration on agarose gel is compared with those expected.
Example 22: Effectiveness on animals The recombinant vaccines and plasmid vaccines are injected twice at approximately two week intervals into approximately seven day old, unvaccinated SPF chickens by the intramuscular route and in a volume of approximately 0.1 ml. An unvaccinated control group is included in the study.
The chickens are challenged by subcutaneous administration into the neck of lO^TCIDso of pathogenic WN virus.
Viremia, antibody response arid mortality are observed. Autopsies are carried out to observe lesions.
Example 23: Titration anti-WNV neutralizing antibodies Dilution series are produced for each serum at a rate of 3 in DMEM medium to which was added 10% fetal calf serum in 96 well plates of the cellular culture type. To 0.05 ml of diluted serum is added 0.05 ml of culture medium containing approximately 100 CCIP50/ml of WNV. This mixture is incubated for 2 hours at 37°C in an oven in an atmosphere containing 5% C02. 0.15 ml of a suspension of VE O cells containing approximately 100,000 cells/ml was then added to each mixture. The cytopathic effect (CPE) was observed by phase contrast microscopy after 4 to 5 days culturing at 37°C in an atmosphere containing 5% C02. The neutralizing titers of each serum are calculated using the KaYber method. The titers are given in the form of the largest dilution inhibiting the cytopathic effect for 50% - 32 - 158204/2 of the wells. The titers are expressed in Iog10 VN50. Each serum is titrated at least twice and preferably four times.
Example 24: Test on horses of vCP2017 Recombinant vaccines containing vCP2017 (example 18) formulated extemporaneously with 1 ml of Carbopol© 974P adjuvant (4 mg/ml) were injected twice at 35 day intervals into horses aged more than three months and which had not been previously vaccinated, using the intramuscular route and a volume of approximately 1 ml. These groups of animals were vaccinated, with doses of 10S 8CCID50 (i.e. 10564 pfu) for group 1 , 106 8CCID50 (i.e. 106 64 pfu) for group 2 and 107-8CCID50 (i.e. \0™ pfu) for group 3. An unvaccinated control group was included in the study.
The serology was observed. The neutralizing antibody titers were established and expressed in log10 VN50, as indicated in example 23.
Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
Sections of the description and the drawings, which are not within the scope of the claims, do not constitute part of the claimed invention.
Claims (23)
1. A vaccine composition to induce a protective immune response against West Nile virus (WNV) in an animal susceptible to WNV, said composition comprising a vector comprising a recombinant virus or DNA plasmid that encodes and expresses in vivo in the animal WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E, provided that when said virus is avipox virus, said expressed protein is different from WNV polyprotein prM-M-E.
2. The vaccine composition of claim 1 wherein the recombinant virus is a recombinant adenovirus, herpesvirus or poxvirus.
3. The vaccine composition of claim 2 wherein the recombinant virus is a recombinant poxvirus.
4. The vaccine composition of claim 3 wherein the recombinant poxvirus is a recombinant avipox virus.
5. The vaccine composition of claim 4 wherein the recombinant avipox virus is a cannarypox or fowlpox virus.
6. The vaccine composition of claim 5 wherein the canarypox virus is ALVAC and the fowlpox virus is TROVAC.
7. The vaccine composition of claim 1 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E.
8. The vaccine composition of claim 5 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E.
9. The vaccine composition of claim 6 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E.
10. The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-741, 742-966 and 967-2469 of GenBank AF 196835 (SEQ ID NO:66) encoding WNV prM, M and E, respectively.
11. The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E.
12. The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 421-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E and the signal peptide of prM.
13. The vaccine composition of claim 1, further comprising an adjuvant. - 34 - 158204/4
14. The vaccine composition according wherein the adjuvant is a carbomer.
15. The vaccine composition of claim 1 further comprising an antigen or immunogen or epitope thereof of a pathogen other than WNV of the animal, or a vector that contains and expresses in vivo in the animal a nucleic acid molecule encoding the antigen, immunogen or epitope thereof, or an inactivated or attenuated pathogen other than WNV of the animal.
16. The vaccine composition of claim 1, wherein the animal is a cat or a horse.
17. A method for inducing a protective immune response against WNV in an animal comprising administering to the animal the vaccine composition according to claim 1.
18. A method for inducing a protective response against WNV in an animal comprising administering to the animal the composition according to claim 1 , wherein the composition additionally comprises an adjuvant.
19. The method according to claim 18 wherein the adjuvant comprises a carbomer adjuvant.
20. A method for inducing a protective immune response against WNV and a second pathogen in an animal comprising administering to the animal the vaccine composition according to claim 15.
21. A method for inducing a protective immune response against WNV in an animal comprising administering to the animal (a) the vaccine composition according to claim 1, and (b) a WNV isolated- antigen,- immunogen or epitope thereof, .wherein (a) is administered prior to (b) in a prime-boost regimen, or (b) is administered prior to (a) in a prime-boost regimen, or (a) and (b) are administered together, either sequentially or in admixture.
22. The. method of. any of. claims 17, 20 or 21, wherein the animal. is a cat or a horse.
23. The vaccine composition according to claim 1, wherein said composition comprising a vector comprising a recombinant virus or DNA plasmid that encodes and expresses in vivo in the animal WNV polyprotein prM-M-E. For the Applicants, REINHOLD COHN AND PARTNERS By: 1 SEQUENCE LISTING <110> Merial <120> Vaccine against West Nile virus. <130> XXXX <160> 29 <170> Patentln version 3.0 <210> 1 <211 > 30 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 1 ttttttgaat tcgttaccct ctctaacttc 30 <210> 2 <211 > 33 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 2 tttttttcta gattacctcc gactgcgtct tga 33 <210> 3 <211> 40 <212> DNA <213> Artificial 2 <220> <223> oligonucleotide <400> 3 gatctgcagc acgtgtctag aggatatcga attcgcggcc 40 <210> 4 <211> 40 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 4 gatccgcggc cgcgaattcg atatcctcta gacacgtgct 40 <210> 5 <211> 30 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 5 ttttttgaat tctcactgac agtgcagaca 30 <210> 6 <211> 33 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 6 tttttttcta gattagctgt aagctggggc cac 33 3 <210> 7 <21 1> 30 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 7 ttttttgaat tcttcaactg ccttggaatg 30 <210> 8 <211> 33 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 8 tttttttcta gattaagcgt gcacgttcac gga 33 <210> 9 <211> 36 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 9 ttttttgata tcaccggaat tgcagtcatg attggc 36 <210> 10 <211> 36 <212> DNA <213> Artificial <220> <223> oligonucleotide 4 <400> 10 ttttttgata tcatgtataa tgctgatatg attgac 36 <210> 11 <211 > 36 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 11 tttttttcta gattaacgtt ttcccgaggc gaagtc 36 <210> 12 <211 > 42 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 12 atcatcgagc tccagctgta attcatggtc gaaaagaagt gc 42 <210> 13 <211 > 73 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 13 gaattcctcg agctgcagcc cgggttttta tagctaatta gtcatttttt gagagtacca 60 cttcagctac etc 73 <210> 14 <211 > 72 5 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 14 cccgggctgc agctcgagga attcttttta ttgattaact agtcattata aagatctaaa 60 atgcataatt tc 72 <210> 15 <211 > 45 <212> DNA <213> Artificial <220> <223> oligonucleotide . <400> 15 ' gatgatggta ccgtaaacaa atataatgaa aagtattcta aacta 45 <210> 16 <211> 34 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 16 aaacccgggt tctttattct atacttaaaa agtg 34 <210> 17 <21 > 43 <212> DNA <2 3> Artificial <220> <223> oligonucleotide 6 <400> 17 aaaagaattc gtcgactacg atacaaactt aacggatatc gcg 43 <210> 18 <211> 33 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 18 ttttcgcgaa ccggaattgc agtcatgatt ggc 33 <210> 19 <211> 39 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 19 ttttgtcgac gcggccgctt aagcgtgcac gttcacgga 39 <210> 20 <211 > 42 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 20 atcatcgagc tcgcggccgc ctatcaaaag tcttaatgag tt 42 <210> 21 <211 > 73 <212> DNA 7 <213> Artificial <220> <223> oligonucleotide <400> 21 gaattcctcg agctgcagcc cgggttttta tagctaatta gtcatttttt cgtaagtaag tatttttatt taa 73 <210> 22 <211> 72 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 22 cccgggctgc agctcgagga attcttttta ttgattaact agtcaaatga gtatatataa ttgaaaaagt aa 72 <210> 23 <211> 45 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 23 gatgatggta ccttcataaa tacaagtttg attaaactta agttg <210> 24 <211 > 33 <212> DNA <213> Artificial <220> <223> oligonucleotide 8 <400> 24 aaacccgggc ggtggtttgc gattccgaaa tct <210> 25 <211> 43 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 25 aaaagaattc ggatccgatt aaacctaaat aattgtactt tgt 43 <210> 26 <211> 33 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 26 tttcacgtga tgtataatgc tgatatgatt gac 33 <210> 27 <211 > 42 <212> DNA <213> Artificial <220> <223> oligonucleotide <400> 27 ttttggatcc gcggccgctt aacgttttcc cgaggcgaag <210> 28 <211 > 39 <212> DNA <213> artificial oligonucleotide <400> 28 ttttttgata tcatgaccgg aattgcagtc atgattggc <210> 29 <21 1 > 36 <212> DNA <213> artificial oligonucleotide <400> 29 ttttcgcgaa tgaccggaat tgcagtcatg attggc
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0104737A FR2823222B1 (en) | 2001-04-06 | 2001-04-06 | VACCINE AGAINST NILE FEVER VIRUS |
PCT/FR2002/001200 WO2002081621A2 (en) | 2001-04-06 | 2002-04-05 | Vaccine against the nile fever virus |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158204A true IL158204A (en) | 2013-03-24 |
Family
ID=8862055
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15820402A IL158204A0 (en) | 2001-04-06 | 2002-04-05 | Vaccine against the nile fever virus |
IL158204A IL158204A (en) | 2001-04-06 | 2003-10-01 | Vaccine composition for inducing a protective immune response against the west nile virus |
IL185263A IL185263A0 (en) | 2001-04-06 | 2007-08-14 | Vaccine against the nile fever virus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15820402A IL158204A0 (en) | 2001-04-06 | 2002-04-05 | Vaccine against the nile fever virus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL185263A IL185263A0 (en) | 2001-04-06 | 2007-08-14 | Vaccine against the nile fever virus |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1377660B1 (en) |
JP (1) | JP4426761B2 (en) |
AU (1) | AU2002307971B2 (en) |
BE (1) | BE2016C021I2 (en) |
BR (1) | BRPI0208896B1 (en) |
CA (1) | CA2448796C (en) |
CY (2) | CY1117676T1 (en) |
DK (1) | DK1377660T3 (en) |
ES (2) | ES2566044T3 (en) |
FR (2) | FR2823222B1 (en) |
HK (2) | HK1061868A1 (en) |
HU (2) | HU230122B1 (en) |
IL (3) | IL158204A0 (en) |
LT (1) | LTC1377660I2 (en) |
LU (1) | LU93048I2 (en) |
MX (1) | MXPA03008998A (en) |
NL (1) | NL300806I2 (en) |
PL (2) | PL210306B1 (en) |
RU (1) | RU2283138C2 (en) |
SI (1) | SI1377660T1 (en) |
WO (1) | WO2002081621A2 (en) |
ZA (1) | ZA200307620B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2464228C (en) | 2000-10-27 | 2017-01-17 | Immuno-Rx, Inc. | Vaccine immunotherapy for immune suppressed patients |
PL220846B1 (en) | 2001-07-27 | 2016-01-29 | Wyeth Corp | Vaccine composition against West Nile virus infection |
AU2003296974A1 (en) * | 2002-12-13 | 2004-07-14 | Aventis Pasteur, Inc. | Production of alvac on avian embryonic stem cells |
CA2526640C (en) | 2003-05-23 | 2014-07-15 | Chiron Corporation | Immunogenic reagents from west nile virus |
WO2006029300A2 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
MY147379A (en) | 2005-12-02 | 2012-11-30 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
SG193821A1 (en) | 2008-08-29 | 2013-10-30 | Boehringer Ingelheim Vetmed | West nile virus vaccine |
ES2550179T3 (en) | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Chimeric Newcastle disease viruses and uses thereof |
AU2010229675B2 (en) | 2009-03-27 | 2016-02-25 | Academia Sinica | Methods and compositions for immunization against virus |
JP5797190B2 (en) * | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス, インコーポレイテッド | Vaccine immunotherapy |
TWI537385B (en) | 2010-11-04 | 2016-06-11 | 中央研究院 | Methods for producing virus particles with simplified glycosylation of surface proteins |
RU2506093C1 (en) * | 2012-12-06 | 2014-02-10 | Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук | Method for specific prevention of herd equine rhinopneumonia, salmonella abortion and strangles with using associated vaccine |
SG11201507412SA (en) | 2013-03-14 | 2015-10-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
JP6857498B2 (en) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Combination method for treating cancer |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DE3584341D1 (en) | 1984-08-24 | 1991-11-14 | Upjohn Co | RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
NZ221790A (en) | 1986-09-12 | 1990-07-26 | Genentech Inc | Method for the continuous production of a heterologous protein in a eukaryotic host cell |
DE3743138A1 (en) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | SLIP RINGLESS, ELECTROMAGNETIC OVERLOAD CLUTCH |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
FR2702373B1 (en) | 1993-03-08 | 1996-06-07 | Rhone Merieux | Water-in-oil fluid vaccine emulsions containing a metabolizable oil. |
EP0668355B1 (en) | 1993-12-20 | 1999-04-07 | Akzo Nobel N.V. | Vaccine for the protection of horses against equine herpesvirus infection |
FR2728794B1 (en) | 1994-12-30 | 1997-03-21 | Rhone Merieux | AVIAN RECOMBINANT VACCINE BASED ON AVIAN HERPES VIRUS, PARTICULARLY AGAINST GUMBORO DISEASE |
FR2728795B1 (en) | 1994-12-30 | 1997-03-21 | Rhone Merieux | AVIAN RECOMBINANT LIVING VACCINE USING AVIAN HERPES VIRUS AS A VECTOR |
CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
DE69740033D1 (en) | 1996-07-03 | 2010-12-09 | Merial Inc | RECOMBINANT DOG ADENOVIRUS 2 (CAV2), WHICH CONTAINS EXOGENOUS DNA |
FR2751226B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES |
FR2751225B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | AVIAN POLYNUCLEOTIDE VACCINE FORMULA |
FR2751227B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS |
ES2241042T3 (en) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
CN1187088C (en) * | 1997-02-28 | 2005-02-02 | 阿坎姆比斯公司 | Chimeric flavirirus vaccines |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
US6416763B1 (en) * | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
PL210451B1 (en) | 1999-06-10 | 2012-01-31 | Merial Sas | DNA vaccines for domestic and sports animals |
FR2796397B1 (en) | 1999-07-16 | 2006-09-01 | Merial Sas | FELIN CALICIVIRUS GENES AND VACCINES, INCLUDING RECOMBINANT VACCINES |
-
2001
- 2001-04-06 FR FR0104737A patent/FR2823222B1/en not_active Expired - Lifetime
-
2002
- 2002-04-05 HU HU0401868A patent/HU230122B1/en active Protection Beyond IP Right Term
- 2002-04-05 PL PL391444A patent/PL210306B1/en unknown
- 2002-04-05 MX MXPA03008998A patent/MXPA03008998A/en active IP Right Grant
- 2002-04-05 CA CA2448796A patent/CA2448796C/en not_active Expired - Lifetime
- 2002-04-05 AU AU2002307971A patent/AU2002307971B2/en not_active Expired
- 2002-04-05 RU RU2003132455/13A patent/RU2283138C2/en active
- 2002-04-05 WO PCT/FR2002/001200 patent/WO2002081621A2/en active Search and Examination
- 2002-04-05 ES ES02759818.4T patent/ES2566044T3/en not_active Expired - Lifetime
- 2002-04-05 JP JP2002579985A patent/JP4426761B2/en not_active Expired - Lifetime
- 2002-04-05 EP EP02759818.4A patent/EP1377660B1/en not_active Expired - Lifetime
- 2002-04-05 IL IL15820402A patent/IL158204A0/en unknown
- 2002-04-05 BR BRPI0208896A patent/BRPI0208896B1/en active IP Right Grant
- 2002-04-05 SI SI200231069A patent/SI1377660T1/en unknown
- 2002-04-05 EP EP15162832.8A patent/EP2979705B1/en not_active Expired - Lifetime
- 2002-04-05 PL PL365210A patent/PL207584B1/en unknown
- 2002-04-05 DK DK02759818.4T patent/DK1377660T3/en active
- 2002-04-05 ES ES15162832T patent/ES2767413T3/en not_active Expired - Lifetime
-
2003
- 2003-09-30 ZA ZA2003/07620A patent/ZA200307620B/en unknown
- 2003-10-01 IL IL158204A patent/IL158204A/en active IP Right Grant
-
2004
- 2004-07-02 HK HK04104755.3A patent/HK1061868A1/en not_active IP Right Cessation
- 2004-07-02 HK HK16106775.0A patent/HK1219412A1/en not_active IP Right Cessation
-
2007
- 2007-08-14 IL IL185263A patent/IL185263A0/en active IP Right Grant
-
2015
- 2015-09-18 HU HUS1500047C patent/HUS1500047I1/en unknown
-
2016
- 2016-04-06 CY CY20161100275T patent/CY1117676T1/en unknown
- 2016-04-19 FR FR16C0014C patent/FR16C0014I2/en active Active
- 2016-04-20 NL NL300806C patent/NL300806I2/nl unknown
- 2016-04-20 LT LTPA2016011C patent/LTC1377660I2/en unknown
- 2016-04-26 BE BE2016C021C patent/BE2016C021I2/fr unknown
- 2016-04-26 LU LU93048C patent/LU93048I2/en unknown
- 2016-05-20 CY CY2016018C patent/CY2016018I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030104008A1 (en) | Recombinant vaccine against west nile virus | |
US8535682B2 (en) | Recombinant vaccine against West Nile Virus | |
AU2007293474C1 (en) | Recombinant vaccine against bluetongue virus | |
CA2448796C (en) | Vaccine against the nile fever virus | |
AU2009308331C1 (en) | Vaccine against African Horse Sickness Virus | |
US20040037848A1 (en) | Recombinant vaccine against West Nile Virus | |
US8008268B2 (en) | Vaccines against vesicular stomatitis | |
US20050031641A1 (en) | Recombinant vaccine against West Nile Virus | |
CA2448620C (en) | Vaccination against the feline immunodeficiency virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |